Abstract
This 96-week, open-label, randomized study assessed changes in body composition in treatment-naive patients infected with human immunodeficiency virus type 1 who were treated with either atazanavir or ritonavir-boosted atazanavir, in combination with stavudine and lamivudine. Both treatment groups had similar increases in trunk fat, but patients treated with ritonavir-boosted atazanavir had a significantly lower incidence of lipoatrophy.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Anti-HIV Agents / adverse effects*
-
Anti-HIV Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active / adverse effects*
-
Atazanavir Sulfate
-
Body Composition / drug effects*
-
Female
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1 / isolation & purification
-
Humans
-
Lamivudine / adverse effects*
-
Lamivudine / therapeutic use
-
Male
-
Oligopeptides / adverse effects*
-
Oligopeptides / therapeutic use
-
Pyridines / adverse effects*
-
Pyridines / therapeutic use
-
Ritonavir / therapeutic use
-
Stavudine / adverse effects*
-
Stavudine / therapeutic use
Substances
-
Anti-HIV Agents
-
Oligopeptides
-
Pyridines
-
Lamivudine
-
Atazanavir Sulfate
-
Stavudine
-
Ritonavir